Mechanisms of Immune Modulation Mediated by Yeast-derived Particulate Beta-Glucan

酵母来源的β-葡聚糖颗粒介导的免疫调节机制

• 批准号: 8301023
• 负责人: JUN YAN
• 金额: $ 35.89万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-28 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8301023
• 关键词: 3-Dimensional; Address; Adjuvant; Affinity; Anti-Infective Agents; Antibodies; Antigens; Apoptotic; Asians; Bacteria; Barley; Binding; Biological Models; Biological Process; Biological Response Modifiers; Bone Marrow; C3bi; CD4 Positive T Lymphocytes; CD8B1 gene; Cell Maturation; Cells; Clinical; Clinical Trials; Complement; Complement 3a; Complement 5a; Complement Activation; Complementary and alternative medicine; Data; Dendritic Cells; Dendritic cell activation; Deposition; Effector Cell; Frequencies; Glucans; Glucose; Helper-Inducer T-Lymphocyte; Host Defense Mechanism; Human; ITGAM gene; ITGB2 gene; Immune response; Immunity; Immunotherapeutic agent; Immunotherapy; In Vitro; Individual; Infection; Integrins; Interleukin-12; Knowledge; Lactosylceramides; Lectin; Lewis Lung Carcinoma; Ligands; Link; Macrophage-1 Antigen; Malignant Neoplasms; Mediating; Medicine; Modeling; Molecular Mechanisms of Action; Molecular Weight; Monoclonal Antibodies; Mucin-1 Staining Method; Mus; Myelogenous; Oral; Ovalbumin; Particulate; Pathway interactions; Production; Protocols documentation; Regulatory T-Lymphocyte; Reporting; Side; Signal Pathway; Site; Solubility; Structure; T cell differentiation; T cell response; T-Lymphocyte; Testing; Toll-Like Receptor Pathway; Treatment Efficacy; Tumor Antigens; Vertebral column; Work; Xenograft procedure; Yeasts; activation product; base; beta-Glucans; clinical application; complement system; cytokine; cytotoxic; cytotoxicity; dectin 1; design; experience; fungus; immunoregulation; in vivo; interest; macrophage; microbial; neoplastic cell; public health relevance; receptor; response; scavenger receptor; success; tool; tumor

DESCRIPTION (provided by applicant): The use of ¿-glucans in complementary and alternative medicine (CAM) has prevailed for centuries in traditional Asian medicine. However, their clinical use against malignancies in Western medicine has experienced an oscillating success due to a lack of understanding in their exact mechanisms of action. We have previously demonstrated that soluble yeast ¿-glucan of low molecular weight is capable of binding to the lectin site of complement receptor 3 (CR3, CD11b/CD18) and priming CR3+ effector cells for cytotoxicity of iC3b-opsonized tumor cells. The work presented here shows that particulate yeast ¿-glucan has more unique features than soluble ¿-glucan. The objective of the proposed study is to elucidate the cellular and molecular mechanisms of action for particulate ¿-glucan in tumor immunotherapy. Preliminary studies demonstrated that particulate ¿-glucan, not soluble ¿-glucan, stimulated macrophages and dendritic cells (DCs) for activation and proinflammatory cytokine production. Furthermore, orally administered particulate ¿-glucan stimulated DCs that captured apoptotic tumor cells for activation and maturation, leading to the enhanced anti-tumor CD4 and CD8 T cell responses. Strikingly, oral particulate ¿-glucan treatment altered the tumor microenvironment toward Th1 response. Particulate ¿-glucan was also shown to activate the complement system via an alternative pathway, leading to C5a deposition on tumors. These preliminary data provide a strong basis for the current study. Aim 1 will dissect which signaling pathway(s) may be critical for particulate ¿-glucan-mediated DC activation and cytokine release. Toll-like receptor pathway MyD-88- and TRIF-deficient mice, CR3-deficient mice, and dectin-1 pathway dectin-1- and CARD9-deficient mice will be used to address this issue. In addition, T cell differentiation (Th1, Th2, and Th17) in the presence of particulate yeast ¿-glucan stimulated DCs will be examined both in vitro and in vivo. Aim 2 will test the hypothesis that particulate ¿-glucan modulates suppressive cells existing in the tumor microenvironment thereby promoting Th1 response. The function of myeloid-derived suppressive cells (MDSCs), dynamic interaction between regulatory T cells (Treg) and Th17 cells, cross-talk between MDSCs and tumor-infiltrating macrophages will be examined. Lewis lung carcinoma transfected with surrogate antigen ovalbumin and tumor-associated antigen MUC1 will be used as the model systems to address those issues. Aim 3 will test the hypothesis that particulate ¿-glucan stimulated complement activation may be partially contributed to the enhanced anti-tumor T cell responses. Furthermore, the requirement for C3a and/or C5a and their receptors, C3aR and C5aR, as modulators of anti-tumor T cell responses will be determined. Further knowledge of the mechanisms involved in these effects of particulate ¿-glucan will be of great value in the design of effective clinical applications. Public Health Relevance: This study will elucidate the cellular and molecular mechanisms of action of particulate yeast ¿-glucan in tumor immunotherapy. The data generated in this study will allow for the rational design of immunotherapeutic protocols usable in clinical trials.

描述（由申请人提供）：在补充和替代医学（CAM）中使用¿-葡聚糖在传统亚洲医学中已经流行了几个世纪。然而，由于缺乏对其确切作用机制的了解，它们在西方医学中对恶性肿瘤的临床应用取得了摇摆不定的成功。我们之前已经证明，低分子量的可溶性酵母¿-葡聚糖能够结合到补体受体3 （CR3, CD11b/CD18）的凝集素位点，并启动CR3+效应细胞对iC3b-opsonized肿瘤细胞的细胞毒性。本文的研究表明，颗粒酵母-葡聚糖比可溶性-葡聚糖具有更多独特的特征。本研究的目的是阐明颗粒-葡聚糖在肿瘤免疫治疗中的细胞和分子作用机制。

项目成果

Differential developmental requirement and peripheral regulation for dermal Vγ4 and Vγ6T17 cells in health and inflammation.

• DOI: 10.1038/ncomms4986
• 发表时间: 2014-06-09
• 期刊: Nature communications
• 影响因子: 16.6
• 作者: Cai Y;Xue F;Fleming C;Yang J;Ding C;Ma Y;Liu M;Zhang HG;Zheng J;Xiong N;Yan J
• 通讯作者: Yan J